Compare Cipla with J.B.Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs J.B.CHEMICALS - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA J.B.CHEMICALS CIPLA/
J.B.CHEMICALS
 
P/E (TTM) x 30.6 30.2 101.2% View Chart
P/BV x 4.3 6.7 63.8% View Chart
Dividend Yield % 0.5 1.0 49.1%  

Financials

 CIPLA   J.B.CHEMICALS
EQUITY SHARE DATA
    CIPLA
Mar-21
J.B.CHEMICALS
Mar-21
CIPLA/
J.B.CHEMICALS
5-Yr Chart
Click to enlarge
High Rs8791,318 66.7%   
Low Rs411443 92.7%   
Sales per share (Unadj.) Rs237.6264.3 89.9%  
Earnings per share (Unadj.) Rs29.858.0 51.3%  
Cash flow per share (Unadj.) Rs43.066.9 64.3%  
Dividends per share (Unadj.) Rs5.0016.50 30.3%  
Avg Dividend yield %0.81.9 41.4%  
Book value per share (Unadj.) Rs226.7234.2 96.8%  
Shares outstanding (eoy) m806.4677.28 1,043.6%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x2.73.3 81.4%   
Avg P/E ratio x21.615.2 142.7%  
P/CF ratio (eoy) x15.013.2 113.9%  
Price / Book Value ratio x2.83.8 75.6%  
Dividend payout %16.828.4 59.1%   
Avg Mkt Cap Rs m519,82668,043 764.0%   
No. of employees `000NANA-   
Total wages/salary Rs m32,5183,406 954.7%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m191,59620,425 938.0%  
Other income Rs m2,6981,166 231.3%   
Total revenues Rs m194,29421,591 899.9%   
Gross profit Rs m42,4875,562 763.9%  
Depreciation Rs m10,677687 1,554.9%   
Interest Rs m1,60772 2,219.3%   
Profit before tax Rs m32,9015,969 551.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,8881,484 599.0%   
Profit after tax Rs m24,0134,485 535.4%  
Gross profit margin %22.227.2 81.4%  
Effective tax rate %27.024.9 108.7%   
Net profit margin %12.522.0 57.1%  
BALANCE SHEET DATA
Current assets Rs m132,09518,939 697.5%   
Current liabilities Rs m45,9166,866 668.8%   
Net working cap to sales %45.059.1 76.1%  
Current ratio x2.92.8 104.3%  
Inventory Days Days68122 55.3%  
Debtors Days Days7695 0.9%  
Net fixed assets Rs m116,2776,786 1,713.6%   
Share capital Rs m1,613155 1,043.5%   
"Free" reserves Rs m181,23217,943 1,010.1%   
Net worth Rs m182,84418,097 1,010.3%   
Long term debt Rs m12,0280-   
Total assets Rs m248,37225,725 965.5%  
Interest coverage x21.583.4 25.7%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.80.8 97.2%   
Return on assets %10.317.7 58.2%  
Return on equity %13.124.8 53.0%  
Return on capital %17.733.4 53.0%  
Exports to sales %31.30-   
Imports to sales %10.90-   
Exports (fob) Rs m59,951NA-   
Imports (cif) Rs m20,911NA-   
Fx inflow Rs m68,0519,082 749.3%   
Fx outflow Rs m20,9111,792 1,166.8%   
Net fx Rs m47,1407,290 646.6%   
CASH FLOW
From Operations Rs m37,5523,148 1,192.9%  
From Investments Rs m-23,872-2,307 1,034.9%  
From Financial Activity Rs m-13,299-874 1,521.2%  
Net Cashflow Rs m509-33 -1,553.1%  

Share Holding

Indian Promoters % 13.5 0.0 -  
Foreign collaborators % 20.1 54.0 37.3%  
Indian inst/Mut Fund % 48.6 26.1 186.3%  
FIIs % 26.6 9.2 288.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 46.0 144.3%  
Shareholders   418,584 61,314 682.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   SUN PHARMA    LUPIN    DR. REDDYS LAB    ZYDUS LIFESCIENCES    AUROBINDO PHARMA    



Today's Market

Sensex, Nifty End Marginally Lower; Metal Stocks Witness Selling(Closing)

After opening on a positive note, Indian share markets failed to keep up early gains and ended the day marginally lower.

Related Views on News

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

J B Chemicals & Pharma's Decent Performance Puts Stock in Focus (Views On News)

Aug 13, 2021

The company seeks to expand the market for prescription lozenges with new launches this year.

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)

May 19, 2022

During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.

More Views on News

Most Popular

2022's Best Performing Penny Stocks So Far...(Views On News)

Mar 2, 2022

We are just two months into 2022 and several penny stocks that we track have already surged 5x.

5 Debt Free Penny Stocks with Good Profitability to Watch Out for in 2022(Views On News)

Mar 16, 2022

Debt free penny stocks are vital when it's a question of portfolio diversification in a volatile market. They can potentially offer good profitability in the long run.

Penny Stocks to Buy and Hold Beyond 2022(Views On News)

Apr 6, 2022

A step-by-step method to pick the best penny stocks for the long term.

6 Penny Stocks that Could Be Hidden Bluechips. Take a Look...(Views On News)

Apr 13, 2022

These penny stocks can become future multibaggers. Watch out for them.

Adani Power vs Tata Power: Which Power Stock is Better?(Views On News)

Feb 28, 2022

Rising electricity consumption provides a lot of scope for growth. Which company has a better chance at capturing it?

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


May 23, 2022 (Close)

TRACK CIPLA

CIPLA - IPCA LABS COMPARISON

COMPARE CIPLA WITH

MARKET STATS